Tony Evnin. Tony joined Venrock in 1974 and built the firm’s healthcare franchise, helping to shape the modern biotechnology industry. He currently serves on the Board of Directors of three public companies, including AVEO Pharmaceuticals (NASDAQ: AVEO) and Infinity Pharmaceuticals (NASDAQ: INFI), as well as several private Boards, such as Acceleron Pharmaceuticals, Celladon, Constellation Pharmaceuticals, and Metabolex. Past investments include Centocor (IPO/ acquired by Johnson & Johnson), Coley Pharmaceutical Group (IPO/ acquired by Pfizer), Genetics Institute (IPO/ acquired by Wyeth), Icagen (IPO/ acquired by Pfizer), IDEC Pharmaceuticals (IPO/ merged with Biogen), IDEXX Laboratories (NASDAQ: IDXX), Millennium Pharmaceuticals (IPO/acquired by Takeda) and Sepracor (IPO/acquired by Dainippon Sumitomo).
More than 30 of his investments have been through an IPO during his Venrock tenure. Richard Bradshaw. David Beisel. GenuineVC - GenuineVC - David Beisel. David Beisel (davidbeisel) Fred Aslan. Fred joined Venrock in 2006 and is focused on the medical device and drug development sectors. At Venrock, Fred has led multiple investments, and presently serves on the Board of Directors of Receptos, Inc. Fred is also founder and CEO of ADVANCE Medical, a Venrock portfolio company that is focused on the commercialization of medical technology in Brazil and other countries in Latin America. Prior to Venrock, he was with Atlas Venture assessing investments in medical devices and biotechnology.
Earlier in his career, Fred was director of business development and head of investor relations for CuraGen Corporation, an oncology-focused drug development company. Fred received his B.S. in Biology from Duke University, M.D. from Yale University School of Medicine and M.B.A. from the Harvard Business School.